Home World News FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age... World News FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 879 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Answers to Your Questions About Sunscreen Ingredients April 21, 2022 Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically... March 23, 2023 What to Know About Getting Access to New Cancer Advances Presented... September 14, 2022 New on NCI Websites for July 2019 July 2, 2019 Load more HOT NEWS Weekend in New England Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? Blinatumomab Increases Survival for Infants with an Aggressive Type of ALL EMA Recommends Extending Indications for Lisocabtagene Maraleucel
